Publications

What is a Publication?
13 Publications visible to you, out of a total of 13
Integration of a medication reminder app into the RABBIT-SpA disease registry to record patient data on daily drug usage

Abstract

Not specified

Authors: Anne C. Regierer, Andreas Reich, Anja Weiß, Martin Feuchtenberger, Silke Zinke, Hanns-Martin Lorenz, Uta Syrbe, Peter Böhm, Julius Wiegand, Anja Strangfeld

Date Published: 2025

Publication Type: Journal

Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register

Abstract (Expand)

OBJECTIVES: This analysis aimed to evaluate the effect of depressive symptoms on treatment outcomes in patients with axial spondyloarthritis (axSpA), focusing on low disease activity (LDA) and inactive … disease (ID) at 3 and 6 months after the start of a new systemic therapy. METHODS: This analysis used data from the longitudinal, observational RABBIT-SpA register. Depressive symptoms were assessed using the WHO-5 Well-Being Index, with scores below 29 indicating moderate-to-severe symptoms. The treatment outcomes LDA and ID, based on the Axial Spondyloarthritis Disease Activity Score with C-reactive protein, were evaluated after 3 and 6 months. Logistic regression models adjusted for confounding variables, selected via a directed acyclic graph, were used to assess the relationship between baseline depressive symptoms and treatment outcomes. Multiple imputation was used to handle missing data. RESULTS: A total of 1755 patients with axSpA were included in the analysis. Moderate-to-severe depressive symptoms were present in 29% of patients at baseline. Fewer patients with moderate-to-severe depressive symptoms reached LDA or ID at 3 months and 6 months compared with those with no or mild symptoms. Logistic regression analysis showed that depressive symptoms were associated with lower odds of reaching LDA or ID at both time points. CONCLUSION: Depressive symptoms have a significant and independent negative effect on treatment response in patients with axSpA, particularly in achieving LDA and ID. These findings highlight the importance of routine mental health screening and treatment of depressive symptoms in axSpA management to optimise disease outcomes.

Authors: A. Reich, A. Weiss, L. Lindner, S. Zinke, C. Stille, J. Detert, D. Poddubnyy, A. Strangfeld, X. Baraliakos, A. C. Regierer

Date Published: 2025

Publication Type: Journal

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey

Abstract (Expand)

OBJECTIVES: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and … comorbidities. International collaboration is required to ensure statistical power and to enhance generalizability. The first step forward is identifying which data are currently being collected. Across 17 registries participating in the European Spondyloarthritis Research Collaboration (EuroSpA), we aimed to map recording practices for NMMs, comorbidities and safety outcomes in patients with PsA and axSpA. METHODS: Through a survey with 4,420 questionnaire items, we explored the recording practices of 58 pre-defined conditions (i.e. NMMs, comorbidities and safety outcomes) covering 10 disease areas. In all registries we mapped for each condition whether it was recorded, the recording procedure and the potential to identify it through linkage to other national registries. RESULTS: Conditions were generally recorded at entry into the registry and clinical follow-up visits using a pre-specified list or a coding system. Most registries recorded conditions within the following disease areas: NMMs (number of registries, n = 15-16), cardiovascular diseases (n = 10-14), gastrointestinal diseases (n = 12-13), infections (n = 10-13) and death (n = 14). Nordic countries had the potential for data linkage and generally had limited recording of conditions in their registry, while other countries had comprehensive recording practices. CONCLUSION: A wide range of conditions were consistently recorded across the registries. The recording practices of many conditions and disease areas were comparable across the registries. Our findings support the potential for future collaborative research.

Authors: Z. F. Ahmadzay, J. Heberg, J. B. Jørgensen, L. M. Ørnbjerg, M. Østergaard, S. Møller-Bisgaard, B. Michelsen, A. G. Loft, G. T. Jones, P. Hellamand, A. Scherer, M. J. Nissen, K. Pavelka, J. Závada, K. Laas, S. Vorobjov, D. Nordström, T. Sokka-Isler, A. C. Regierer, A. Reich, B. Gudbjornsson, K. Thorarinsdottir, F. Iannone, E. G. Favalli, M. van de Sande, S. A. Provan, T. K. Kvien, A. M. Rodrigues, C. F. Gonçalves, C. Codreanu, C. Mogosan, Z. Rotar, K. P. Prikmajer, I. Castrejon, L. Otero-Varela, D. Di Giuseppe, J. K. Wallman, A. Ciurea, B. Möller, G. Kenar-Artın, T. D. Yıldırım, G. J. Macfarlane, O. Rotariu, B. Glintborg, M. L. Hetland

Date Published: 2024

Publication Type: Journal

No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry

Abstract (Expand)

BACKGROUND: The potential benefit of methotrexate (MTX) in combination with biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) is still … a matter of debate. OBJECTIVES: To compare clinical and patient reported characteristics as well as drug retention rates in PsA patients receiving b/tsDMARD monotherapy or in combination with MTX. METHODS: RABBIT-SpA is a prospective longitudinal cohort study including axSpA and PsA patients. In this analysis, PsA patients were stratified into two groups: starting b/tsDMARD as monotherapy or in combination with MTX. Treatment retention was compared by drug survival analysis. RESULTS: 69% of the patients (n=900) started b/tsDMARD as monotherapy while 31% were treated in combination with MTX (n=405). At baseline, clinical domains like skin, nail and joint affection, dactylitis, enthesitis and axial involvement were similar between the groups. Only the patients’ satisfaction concerning tolerability of the previous treatment was significantly better in the combination group at treatment start. Drug retention rates did not differ between the groups (p=0.4). At 6/12 months, 66%/48% of patients in monotherapy and 67%/48% in the combination group were still on their original treatment. CONCLUSIONS: We did not identify any clinical parameters with notable influence on the choice of b/tsDMARD mono or MTX-combination therapy in PsA. Drug retention rates are similar between mono and combination therapy. It seems that the decision to continue MTX at initiation of b/tsDMARDs is mostly based on the subjective tolerability of MTX treatment.

Authors: A. C. Regierer, D. Kiefer, G. Schett, A. Krause, A. Weiss, P. Sewerin, A. Strangfeld

Date Published: 2024

Publication Type: Journal

RABBIT-SpA – nationale Registerdaten zu Spondyloarthritiden

Abstract (Expand)

Seit 2017 wird im Deutschen Rheuma-Forschungszentrum das Krankheitsregister RABBIT-SpA für die axiale Spondyloarthritis und die Psoriasis-Arthritis durchgeführt. Fast 80 rheumatologische Einrichtungen … in ganz Deutschland sind aktiv beteiligt. Es liegen inzwischen Daten von je über 1.800 Patient:innen für beide Erkrankungen vor. Da die Patient:innen zu Beginn einer neuen Therapie eingeschlossen werden, ist die Krankheitsaktivität im Vergleich zu anderen Kohorten aus dem Versorgungsalltag relativ hoch. Es wurden bereits einige Analysen der RABBIT-SpA-Patient:innen publiziert. Es konnte zum Beispiel gezeigt werden, dass die Therapieretention bei PsA-Patient:innen, die entweder mit einer b/tsDMARD-Monotherapie oder einer Kombination eines b/tsDMARDs mit MTX behandelt wurden, gleich war. Eine Analyse zur mentalen Gesundheit zeigte, dass bei ca. 30% der Patient:innen depressive Symptome vorliegen, sowohl bei der axSpA als auch bei der PsA. In einer weiteren Analyse wurden PsA-Patient:innen, die auch eine axiale Beteiligung haben mit den axSpA-Patient:innen, die auch eine Hautpsoriasis haben, verglichen. axPsA-Patient:innen waren älter und weniger häufig HLA-B27 positiv, zudem war der Frauenanteil höher, als bei den axSpA+Pso-Patient:innen. Die Krankheitslast gemessen z. B. an der globalen Krankheitsaktivität berichtet sowohl von den Ärzten als auch von den Patient:innen war sehr ähnlich in beiden Gruppen. Damit die Daten aus Krankheitsregistern nutzbringend analysiert werden können und zum Beispiel auch Analysen über Therapiesicherheit möglich sind, ist es wichtig, dass möglichst viele Patient:innen eingeschlossen werden und über eine lange Zeit im Register beobachtet werden. Deshalb freuen wir uns sehr über die aktive Mitarbeit so vieler Rheumtaolog:innen und ihrer Mitarbeiter:innen und heißen neue rheumatologische Einrichtungen jederzeit herzlich willkommen.

Authors: Anne C. Regierer, Anja Weiß

Date Published: 2024

Publication Type: Journal

Correction: Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort

Abstract

Not specified

Authors: A. Reich, A. Weiss, L. Lindner, X. Baraliakos, D. Poddubnyy, S. Zinke, C. Stille, A. Strangfeld, A. C. Regierer

Date Published: 2024

Publication Type: Journal

Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries

Abstract (Expand)

Summary Background and objective Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease affecting the musculoskeletal system, skin and nails. The aim is to characterize sociodemographic … and clinical patient profiles documented in dermatologic and rheumatologic care. Patients and Methods Data of 704 patients with PsA from the dermatological Psoriasis Registry PsoBest (PB) and 1066 patients from the rheumatological disease registry RABBIT-SpA (RS) were analyzed. Comparable anamnestic and clinical variables were identified and descriptively analyzed. Results The mean age was 51.7 years in PB and 51.9 in RS. Disease duration of psoriasis was longer, mean cutaneous severity was higher in PB. However, more patients in RS vs. PB had tender joints and swollen joints. Mean Dermatology Life Quality Index was higher in PB and mean Health Assessment Questionnaire in RS. Patient reported global disease activity and pain were lower in PB. IL-23 inhibitors were used more frequently in PB, and TNF inhibitors in RS. Conclusions Clinical specialization was associated with different clinical and treatment patterns of PsA. This may indicate a selection by dominant manifestation of psoriatic disease and potentially by effects of health care access. Psoriatic arthritis should be treated in a multidisciplinary approach considering all facets of this complex disease.

Authors: Matthias Augustin, Lisa Lindner, Laura Kühl, Anja Weiss, Stephan Jeff Rustenbach, Brigitte Stephan, Martin Feuchtenberger, Ulrich Mrowietz, Diamant Thaçi, Petra Staubach, Xenofon Baraliakos, Anja Strangfeld, Ralph von Kiedrowski, Frank Behrens, Anne Constanze Regierer

Date Published: 2023

Publication Type: Journal

Powered by
 (v.1.17.3)

(LDH: v0.3.4)

About NFDI4Health | About Local Data Hub DRFZ Berlin | Partners and Funding | Credits | Terms & Conditions | Privacy Policy | Imprint
Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH
Additions copyright ...